- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00005800
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel in treating women who have stage III breast cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
- Evaluate the clinical and pathological response rate of sequential doxorubicin and docetaxel chemotherapy in the neoadjuvant treatment of women with stage III breast cancer.
- Measure signal transducer and activator of transcription (STAT) activation before and after this neoadjuvant chemotherapy regimen in this patient population.
- Correlate response to chemotherapy with STAT activation before and after this neoadjuvant chemotherapy regimen in these patients.
- Determine how other potential predictors of response correlate with STAT activation by measuring Bcl-2, Bcl-xL, Bax protein levels, tyrosine kinase levels, growth rate of the tumor, and apoptotic index before and after this neoadjuvant chemotherapy regimen in these patients.
- Correlate response to chemotherapy with levels of STAT activation in association with the presence of Bcl-2 proteins and tyrosine kinases, growth rate of the tumor, and apoptotic index in these patients.
- Evaluate the toxicity of this neoadjuvant chemotherapy regimen given in a dose-dense fashion in these patients.
OUTLINE: Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 5 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Tampa, Florida, Forente stater, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically or pathologically confirmed stage III breast cancer
- Clinical evidence of primary invasive breast tumor greater than 5 cm in dimension (T3) and no evidence of metastatic disease clinically or by staging studies including computed tomography (CT) scan of the chest, abdomen, and pelvis, and a bone scan
- Inflammatory breast carcinoma defined as diffuse brawny induration of the skin of the breast with an erysipeloid edge due to embolization of the dermal lymphatics and pathologic evidence of dermal lymphatic invasion
- No bilateral breast cancer unless synchronous
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- 18 to 70
Sex:
- Female
Menopausal status:
- Not specified
Performance status:
- Eastern Cooperative Oncology Group (ECOG) 0-1
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 3,000/mm^3
- Absolute neutrophil count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin less than 2.0 mg/dL
- SGOT/SGPT less than 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase no greater than 4 times ULN provided SGOT/SGPT no greater than ULN
Renal:
- Creatinine no greater than 1.5 mg/dL
Cardiovascular:
- If prior cardiac event or ischemia on electrocardiogram, must be cleared by cardiologist
- LVEF at least 50% by resting MUGA
- No severe cardiac dysfunction
- No prior or concurrent angina pectoris, congestive heart failure, or major ventricular arrhythmias
- No uncontrolled essential hypertension
Other:
- Not pregnant or nursing
- Fertile patients must use effective nonhormonal barrier contraception
- No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or intraductal or lobular carcinoma in situ of the breast
- No other serious medical or psychiatric illness that would preclude study consent or treatment
- No prior severe and intolerable reactions to filgrastim (G-CSF)
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy to the breast
Surgery:
- Not specified
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Dose-Dense Chemotherapy
Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses.
After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses.
Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course.
Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
|
Andre navn:
Andre navn:
Andre navn:
Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pathological Response Rate
Tidsramme: 7 years
|
Evaluate the pathological response rate of sequential doxorubicin and docetaxel chemotherapy in the neoadjuvant treatment of women with stage III breast cancer.
Pathologic response is classified as either complete pathologic response or partial pathologic response based on the size of residual tumor after treatment (complete pathologic response if 0 cm, partial pathologic response if >0 cm).
|
7 years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Susan Minton, D.O., H. Lee Moffitt Cancer Center and Research Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Neoplasmer
- Neoplasmer etter nettsted
- Bryst sykdommer
- Brystneoplasmer
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Antibiotika, antineoplastisk
- Docetaxel
- Doxorubicin
- Liposomal doksorubicin
Andre studie-ID-numre
- MCC-11971
- CA 82533 (Annen identifikator: NCI)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på Docetaxel
-
Tianjin Medical University Cancer Institute and...Rekruttering
-
Zhuhai Beihai Biotech Co., LtdFullførtSolide svulster | Bioekvivalens | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaFullførtIkke-småcellet lungekreft (NSCLC)Kina
-
Optimal Health ResearchFullførtBrystkreft | Lungekreft | ProstatakreftForente stater
-
Fudan UniversityHar ikke rekruttert ennåAvansert ikke-småcellet lungekreft
-
Hunan Cancer HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People...UkjentIkke-småcellet lungekreftKina
-
Seoul National University HospitalClinical Research Center for Solid Tumor, KoreaAvsluttetPlateepitelkarsinom i hode og nakkeKorea, Republikken
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaAvsluttetIkke plateepitel, ikke småcellet lungeKina
-
University of OxfordUkjent